We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+18.67%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.32B
AUM Growth
+$20.1M
Cap. Flow
+$138M
Cap. Flow %
10.43%
Top 10 Hldgs %
45.62%
Holding
85
New
8
Increased
16
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$19.7M
2
ALT icon
Altimmune
ALT
+$18.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$17.5M
4
SWTX
SpringWorks Therapeutics
SWTX
+$17.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$54M
2
IGMS
IGM Biosciences
IGMS
+$10.8M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.98M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.68M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$6.3M

Sector Composition

Rank Sector Weight
1 Healthcare 94.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
51
Celldex Therapeutics
CLDX
$3.26B
$5.39M 0.41%
+200,000
New +$5.81M
TYRA icon
52
Tyra Biosciences
TYRA
$1.61B
$5.32M 0.4%
743,988
-13,444
-2% -$107K
TRML
53
DELISTED
Tourmaline Bio
TRML
$5.3M 0.4%
117,472
– –
ASND icon
54
Ascendis Pharma A/S
ASND
$16.4B
$4.65M 0.35%
50,000
– –
PLRX icon
55
Pliant Therapeutics
PLRX
$65M
$3.86M 0.29%
482,413
– –
AKRO
56
DELISTED
Akero Therapeutics
AKRO
$3.82M 0.29%
403,787
– –
ICVX
57
DELISTED
Icosavax, Inc. Common Stock
ICVX
$3.73M 0.28%
651,393
+225,000
+53% +$1.76M
ELDN icon
58
Eledon Pharmaceuticals
ELDN
$267M
$3.18M 0.24%
1,305,095
– –
ELEV
59
DELISTED
Elevation Oncology
ELEV
$2.78M 0.21%
1,983,168
+3
+0% +$8
KROS icon
60
Keros Therapeutics
KROS
$211M
$2.76M 0.21%
100,000
– –
YMAB
61
DELISTED
Y-mAbs Therapeutics
YMAB
$2.27M 0.17%
150,000
– –
AKUS
62
DELISTED
Akouos Inc
AKUS
$1.85M 0.14%
394,500
– –
DMRA
63
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$1.76M 0.13%
40,810
– –
GOSS icon
64
Gossamer Bio
GOSS
$87.2M
$1.66M 0.13%
198,382
– –
PYXS icon
65
Pyxis Oncology
PYXS
$238M
$1.59M 0.12%
668,854
– –
VIGL
66
DELISTED
Vigil Neuroscience
VIGL
$1.59M 0.12%
616,786
– –
CABA icon
67
Cabaletta Bio
CABA
$450M
$1.22M 0.09%
1,154,424
– –
MGTX icon
68
MeiraGTx Holdings
MGTX
$1.18B
$1.14M 0.09%
150,000
– –
AUTL
69
Autolus Therapeutics
AUTL
$532M
$1.11M 0.08%
392,167
– –
CMMB
70
Chemomab Therapeutics
CMMB
$13.2M
$1.07M 0.08%
72,042
– –
HARP
71
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.03M 0.08%
54,060
– –
ANAB icon
72
AnaptysBio
ANAB
$1.62B
$1.01M 0.08%
50,000
– –
RCOR
73
DELISTED
Renovacor, Inc.
RCOR
$1.01M 0.08%
500,000
– –
GLS
74
DELISTED
Gelesis Holdings, Inc.
GLS
$970K 0.07%
626,108
– –
ATXS
75
DELISTED
Astria Therapeutics
ATXS
$900K 0.07%
300,000
– –
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Cormorant Asset Management held 85 positions worth $1.32B, up 1.5% from $1.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $138M of net new capital in Q2 2022, opening 8 new positions and adding to 16 existing holdings. Its largest new stake was Arcellx: 1,525,000 shares worth $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Turning Point Therapeutics, Inc. Common Stock, an estimated $54M trimmed.

  • Cormorant Asset Management's largest Q2 2022 buy was Arcellx: 1,525,000 shares worth $27.6M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q2 2022, an estimated $17.5M increase.
  • Cormorant Asset Management's biggest Q2 2022 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $54M.
  • Cormorant Asset Management fully exited IGM Biosciences in Q2 2022, selling an estimated $10.8M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $1.32B portfolio in Q2 2022.
  • Cormorant Asset Management opened 8 new positions and closed 5 in Q2 2022.
  • Cormorant Asset Management's portfolio value rose 1.5% quarter-over-quarter to $1.32B.

Based on Cormorant Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.